Vertex Pharmaceuticals Inc. (VRTX: Quote) announced positive results from a viral kinetic study of the nucleotide analogue ALS-2200 after the bell Monday, for the treatment of hepatitis C. There was a median 4.54 log10 reduction in hepatitis C virus RNA in people with genotype 1 chronic hepatitis C who were new to treatment after seven days of dosing with 200 mg of ALS-2200 once daily.
The company also reported second quarter non-GAAP net income of $0.46 per share, which fell short of the consensus estimate of $0.59.
Vertex Pharmaceuticals was range-bound for the majority of Monday's session and closed up by 0.64 at $49.96. The stock finished near the upper end of a one-week range. Vertex is now up 3.79 on 113K shares after the bell.
Click here to receive FREE breaking news email alerts for Vertex Pharmaceuticals Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org